Clinical Trials Logo

Ascites Hepatic clinical trials

View clinical trials related to Ascites Hepatic.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05765253 Terminated - Vascular Diseases Clinical Trials

Achieving Portal Access With Scorpion Post-Approval Study (APASS)

Start date: July 13, 2023
Phase: N/A
Study type: Interventional

Creation of the parenchymal tract between the portal vein and the hepatic vein is the most difficult and time consuming step in a TIPS procedure. The purpose of this study is to evaluate portal vein access sets during the TIPS procedure.

NCT ID: NCT04311489 Terminated - Cirrhosis, Liver Clinical Trials

Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.

ULA04
Start date: August 1, 2020
Phase: Phase 2
Study type: Interventional

This clinical trial intends to investigate the safety, tolerability and efficacy of ularitide on the renal response in patients with liver cirrhosis and refractory ascites for a maximum exposure duration of 48 hours, through a randomized, placebo-controlled, double-blind, single-center trial.

NCT ID: NCT03027635 Terminated - Cirrhosis Clinical Trials

PEriToneal Catheter Versus Repeated Paracentesis for Ascites in Cirrhosis

PETRA
Start date: January 20, 2017
Phase: N/A
Study type: Interventional

Insertion of a tunnelated peritoneal catheter (PleurX) allows repeated intermittent small volume fluid drainage at home. The treatment may improve the management of ascites and have a beneficial effect on the quality of life. This study aims to evaluate the beneficial and harmful effects of the peritoneal catheter (PleurX) versus repeated large volume paracentesis for patients with cirrhosis and diuretic resistant ascites. The trial is an investigator initiated, randomised, single blind, parallel arm, controlled trial. Tunnelated peritoneal (PleurX) catheter versus large volume paracentesis. All patients will receive ciprofloxacin to prevent spontaneous bacterial peritonitis. We will include 32 adult patients with cirrhosis Duration of trial 18 months. The total duration of follow up is six months. The primary outcome is paracentesis free survival.